Aurobindo Acquires Lannett to Deepen US Generics Footprint in Complex, Non-Opioid Controlled Substances

The Indian pharma major bolsters its American specialty generics platform by absorbing a DEA-regulated, technically demanding portfolio—sidestepping opioid-litigation risk that has hobbled sector rivals.

bt-corporate · 6/28/2026, 10:07:10 AM · Ask about this →